Liver cancer risk prediction and treatment study
Part of Cancer, Digestive system clinical trials.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have early-stage liver cancer (stage 0 or A) and are scheduled for surgery to remove it.
- A computer model predicts you have a high chance of the cancer returning.
- Your liver function is good (Child-Pugh class A) and you are well enough for daily activities (ECOG 0 or 1).
- You have had a special MRI scan within the last month that shows clear images of your liver.
- You are willing to have follow-up visits for at least 2 years after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
Hear when a new Hepotacellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.